Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Early Phase 1
1(33.3%)
Phase 1
1(33.3%)
N/A
1(33.3%)
3Total
Early Phase 1(1)
Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07512154Not ApplicableRecruiting

Precision Radiotherapy Enabled by Molecular MRI

Role: collaborator

NCT02287428Phase 1Active Not Recruiting

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Role: collaborator

NCT02060890Completed

Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma

Role: collaborator

NCT02207010Early Phase 1Completed

A Phase 0 Study of AZD1775 in Recurrent GBM Patients

Role: collaborator

All 4 trials loaded